Seattle Genetics Hires Waller To Lead Regulatory Affairs, as SGN-35 Heads to Pivotal Trial

Xconomy Seattle — 

Seattle Genetics, the developer of targeted cancer drugs, said today it has hired Elaine Waller as senior vice president in charge of regulatory affairs. The Bothell, WA-based company (NASDAQ: SGEN) has some big meetings on the docket with U.S. regulators this fall, as it prepares its plan for a pivotal clinical trial of SGN-35 for Hodgkin’s disease. Waller has 20 years’ experience in regulatory affairs, most recently with Bothell, WA-based Sonus Pharmaceuticals.